Applied Clinical Trials June 2018

June 2018 | Volume 27, Issue 6
Applied Clinical Trials June 2018
From the Editor
Editor-in-Chief Lisa Henderson speak about therapeutic needs, rare diseases in children, and the SCORR Marketing survey on innovative or flexible trial designs.
Clinical Trial Insights
Sobering statistics collected on clinical trial execution point to the eventual convergence of healthcare and clinical research operating environments.
By Applied Clinical Trials Editors
Leader of one longtime CRO discusses the marked changes in clinical trial practice from past to present—and the company’s unique focus.
Jill Wechsler details the continued rise of incorporating the “patient experience” in drug development measures.
Peter O’Donnell explores the convergence of policy and science in new vaccine R&D pursuits in Europe.
Feature Article
A look at home and dosing site considerations.
Findings from a new ACT and SCORR Marketing survey reveal the most actively used flexible design approaches in clinical research—many with application in rare disease.
Exploring three distinct patient partnership models to help researchers assess which methods of engagement could work best for their clinical programs.
Outlining the unique pharmacokinetic factors that should be considered when designing and running early stage clinical trials for monoclonal antibodies.
Case study demonstrates that site activation is a key driver in determining patient enrollment cycle time.
A Closing Thought
With more common cancers now increasingly broken down by specific genomic defects, the future of research for any cancer is entirely, and unequivocally, molecular.
lorem ipsum